Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out
Finding a functional cure to HIV is one of the biggest challenges in modern medicine, a task made so
much tougher because of the virus’s ability to incorporate itself permanently into a host’s genome.
But Diaccurate SAB, of Paris, thinks it may have a solution – and it’s all down to a discovery showing
that the virus seems to make crucial immune CD4 cells go “bumpy”, lose their function and die.
It’s an idea that is so intriguing that Diaccurate has managed to bring aboard the Nobel prize winner
Professor Tasuku Honjo, famously credited with the work establishing PD1 as a target in immunooncology,
to chair its scientific advisory board.
Countless companies have tried and failed to find technology that can prevent the destruction of the
immune system. But the team at Diaccurate, a spin-off from the Institut Pasteur in Paris, says tackling
these bumpy and non-functional CD4 cells could be the answer.
Diaccurate CEO Dominique Bridon told BioWorld the foundation of the company is work done by the
institute, which could also be the basis of therapies for other infectious diseases and even cancer.